FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Wants More Makena Info

[ Price : $8.95]

FDA issues a complete response letter seeking more information about Amags application for a single-dose vial of its Makena.

Preemption Defense Alive and Well: Attorneys

[ Price : $8.95]

Two Covington & Burling attorneys say recent court decisions and appeals show that branded drug manufacturers are still making goo...

Shuren Testified Falsely on Morcellators: Activist

[ Price : $8.95]

Anti-morcellator activist Hooman Noorchashm charges that CDRH director Jeffrey Shuren either experienced a critical memory lapse o...

Too Much Being Made of Biosimilar Interchangeability: Woodcock

[ Price : $8.95]

CDER director Janet Woodcock says too much is being made of biosimilar interchangeability and pharmacy substitution as FDA moves t...

Lilly, Merck Extend Combination Drug Pact for Lung Cancer

[ Price : $8.95]

Eli Lilly and Merck extend an existing collaboration to evaluate the combination of Lillys Alimta and Mercks Keytruda in a pivotal...

FDA Releases 3 PMR/PMC Backlog Reports

[ Price : $8.95]

FDA posts its fifth, sixth and seventh reports on backlogs in postmarketing reports and commitments.

FDA Designates Avelumab Breakthrough Therapy

[ Price : $8.95]

FDA says that Merck and Pfizers avelumab is a breakthrough therapy for patients with metastatic Merkel cell carcinoma.

3 Topics at PDUFA 6 Reauthorization Meeting

[ Price : $8.95]

FDA makes presentations biomarkers, the benefit/risk framework, and patient-reported outcomes at a PDUFA 6 reauthorization stakeho...

Final Guidance on LDT Oversight Due Next Year: Shuren

[ Price : $8.95]

CDRH director Jeffrey Shuren says his Center intends to finalize early next year its guidance on aFramework for Regulatory Oversig...

AngioDynamics Resolves Warning Letter on NanoKnife System

[ Price : $8.95]

FDA issues AngioDynamics a close-out letter effectively resolving promotional issues raised in a 2011 Warning Letter involving its...